No Detail Found!

Histopathological Spectrum and Short-term Outcome of Treatment with Cyclophosphamide in Relapsing Steroid-sensitive Nephrotic Syndrome.

Author(s)
Irshad Ali Bajeer Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Sabeeta Khatri Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Veena Tresa Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Seema Hashmi Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Mohammed Mubarak Department of Histopathology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Ali Asghar Lanewala Department of Pediatric Nephrology, Sindh Institute of Urology and Transplantation, Karachi, Pakistan
Abstract
Objective: To determine the short-term outcome of cyclophosphamide (CPO) course in children with relapsing steroid sensitive nephrotic syndrome (SSNS) with different histopathological lesions. Study Design: Descriptive, observational study. Place and Duration of Study: Pediatric Nephrology Department, Sindh Institute of Urology and Transplantation, Karachi, from January 2012 to December 2014. Methodology: All children with relapsing steroid-sensitive nephrotic syndrome, who underwent renal biopsy and received cyclophosphamide therapy, were included and followed up for 2 years. Histopathological features in renal biopsy, duration of treatment, duration of complete remission and complication frequency was noted. Results: Of the total 74 patients, 47 (63.5%) were males and 27 (36.5%) females. Median age with Interquartile range (IQR) at presentation was 5 years (4-7 years). Minimal change disease (MCD) was the most common histopathological diagnosis (n=54, 73%) followed by focal segmental glomerulosclerosis (FSGS) (n=13, 17.5%), mesangioproliferative glomerulonephritis (MesPGN) (n=6, 8.1%), IgA nephropathy (n=1, 1.4%). The median number of glomeruli included in each biopsy sample was 15. The median duration of treatment with CPO was 11 weeks (9 to 13 weeks), whereas the median duration of complete remission post-therapy was 13 months (7-23 months). A median timeframe of 17 months (13-24.2 months) lapsed between establishing the diagnosis of NS and initiating CPO treatment. Leucopenia was noted in six (8.1%) patients. Conclusion: The short-term outcome of relapsing SSNS can be improved with CPO and steroids, with minimum short-term side effects.
Publication Details
Page(s) 436-439
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 6, Year: 2018

Request the full text from PASTIC

References
ArifMK,ArifM,AmjadN., 2016.A histopathological outlook on nephrotic syndrome: A pediatric perspective,Indian J Nephrol 26 188 -
Kuzma-MroczkowskaE,SkrzypczykP,Panczyk-TomaszewskaM., 2016.Levamisole therapy in children with frequently relapsing and steroid-dependent nephrotic syndrome: a single-center experience,Cent Eur J Immunolo 41 243 -
GbadegesinRA,WinnMP,SmoyerWE, 2013.Genetic testing in nephrotic syndrome - challenges and opportunities,Nat Rev Nephrol 9 179 -84
ZaguryA,de OliveiraAL,de Araujo MontalvãoJA,NovaesRH,de SáVM, 2011.Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome,Pediatr Nephrol 26 915 -20
VesterU,KranzB,ZimmermannS,HoyerPF, 2003.Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook,Pediatr Nephrol 18 661 -4
WebbNJ,FrewE,BrettellEA,MilfordDV,BockenhauerD,SaleemMA, 2014.Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial,Trials 15 147 -
HodsonEM,WillisNS,CraigJC, 2007.Corticosteroid therapy for nephrotic syndrome in children,Cochrane Database Syst Rev 4 CD001533 -
HahnD,HodsonEM,WillisNS,CraigJC, 2015.Corticosteroid therapy for nephrotic syndrome in children,Cochrane Libr 18 -
HodsonEM,KnightJF,WillisNS,CraigJC, 2000.Corticosteroid therapy for nephrotic syndrome in children,Cochrane Database Syst Rev 4 CD001533 -
HodsonEM,KnightJF,WillisNS,CraigJC, ., -
HodsonEM,KnightJF,WillisNS,CraigJC, 2003.Corticosteroid therapy for nephrotic syndrome in children,Cochrane Database Syst Rev 1 CD001533 -
HodsonEM,KnightJF,WillisNS,CraigJC, 2005.Corticosteroid therapy for nephrotic syndrome in children,Cochrane Database Syst Rev 1 CD001533 -
UedaN,KunoK,ItoS. Eight, 1990.and 12-week courses of cyclophosphamide in nephrotic syndrome,Arch Dis Child 65 1147 -50
RadhakrishnanJ,CattranDC, 2012.The KDIGO practice guideline on glomerulonephritis: reading between the (guide) linesapplication to the individual patient,Kidney Int 82 840 -56
OemarBS,BrodehlJ, 1987.Cyclophosphamide treatment of steroid dependent nephrotic syndrome - comparison of 8-week with 12-week course,Arch Dis Child 62 1102 -6
GarinEH,PryorND,FennellRS,RichardGA, 1978.Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy,J Pediatr 92 304 -8
TakedaA,OhgushiH,NiimuraF, 1998.Matsutani H. Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome,Pediatr Nephrol 12 746 -50
KyrieleisHA,LevtchenkoEN,WetzelsJF, 2007.Long-term outcome after cyclophosphamide treatment in children with steroiddependent and frequently relapsing minimal change nephrotic syndrome,Am J Kidney Dis 49 592 -7
WebbH,JaureguiberryG,DufekS,TullusK,BockenhauerD, 2016.Cyclophosphamide and rituximab in frequently relapsing/ steroid-dependent nephrotic syndrome,Pediatr Nephrol 31 589 -94
van HusenM,Kemper MJ, 2011.New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome,Pediatr Nephrol 26 881 -92
AzibS,MacherMA,KwonT,DechartresA,AlbertiC,LoiratC, 2011.Cyclophosphamide in steroid-dependent nephrotic syndrome,Pediatr Nephrol 26 927 -32
LanewalaA,MubarakM,KaziJI,AkhterF,SherA,FayyazA, 2012.A clinicopathologic study of primary focal segmental glomerulosclerosis in children,Saudi J Kidney Dis Transplant 23 513 -
MartinelliR,PereiraLJ,SilvaOM,OkumuraAS,RochaH., 2004.Cyclophosphamide in the treatment of focal segmental glomerulosclerosis,Braz J Med Biol Res 37 1365 -72
0

Citations

0

Downloads

152

Views